Efficacy and safety of Dapagliflozin and Glimepiride in combination with Metformin: Randomized clinical trial
DOI:
https://doi.org/10.51985/JBUMDC2024437Keywords:
Type 2 diabetes mellitus, glimepiride, dapagliflozin, fasting blood glucose, glycated hemoglobin`Abstract
Objective: To identify the effective treatment option between dapagliflozin-metformin and glimepiride-metformin combination in patients with type 2 diabetes who were inadequately controlled with metformin monotherapy.
Study design and setting: The present study is randomized, conducted for 12 weeks at the National Medical center, Karachi, Pakistan.
Methodology: The patients were divided into 2 treatment groups; group A was given dapagliflozin-metformin combination, while group B was given glimepiride-metformin combination. The efficacy endpoint of groups was estimated by hemoglobin A1c and fasting blood glucose levels at 0-, 6- and 12-week. While, safety endpoints were identified by analyzing liver function tests, lipid profile tests, renal function test, and urine analysis. The significant difference of data was analyzed by using statistical package of social sciences (SPSS) version 25. The parametric t-test and paired t-test were performed and considered p-value = 0.05 as statistical significant.
Results: Baseline demographics, clinical features of diabetes, levels of liver enzymes, liver function test, renal function test, lipid profile, and urinalysis of randomized patients were similar in both treatment groups by showing p = 0.05. Followed by the initiation of the respective treatment, the baseline change of mean FBG and hemoglobin A1c levels with dapagliflozinmetformin combination was shown significantly reduce more compared to glimepiride-metformin combination (p = 0.05). Conclusion: Dapagliflozin-metformin combination therapy was superior and well-tolerated to regulate glycemic control as compare to glimepiride-metformin combination
References
Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S,
Unwin N, et al. Global and regional diabetes prevalence
estimates for 2019 and projections for 2030 and 2045: Results
from the International Diabetes Federation Diabetes Atlas,
th edition. Diabetes Research and Clinical Practice.
;157:107843. DOI: 10.1016/j.diabres.2019.107843
Kim J, Park S, Kim H, Je NK. National trends in metforminbased combination therapy of oral hypoglycaemic agents for
type 2 diabetes mellitus. European journal of clinical pharmacology. 2019 ;75:1723-30. DOI: 10.1007/s00228-019-02751-
Dahlén AD, Dashi G, Maslov I, Attwood MM, Jonsson J,
Trukhan V, Schiöth HB. Trends in antidiabetic drug discovery:
FDA approved drugs, new drugs in clinical trials and global
sales. Frontiers in Pharmacology. 2022 ;12:807548. DOI:
3389/fphar.2021.807548
Nauck MA, Del Prato S, Durán-García S, Rohwedder K,
Langkilde AM, Sugg J, et al. Durability of glycaemic efficacy
over 2 years with dapagliflozin versus glipizide as add-on
therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, obesity &
metabolism. 2020;16(11):1111-20. DOI: 10.1111/dom.12327
Nauck MA, Del Prato S, Meier JJ, Durán-García S, Rohwedder
K, Elze M, et al. Dapagliflozin versus glipizide as add-on
therapy in patients with type 2 diabetes who have inadequate
glycemic control with metformin: a randomized, 52-week,
double-blind, active-controlled noninferiority trial. Diabetes
Care. 2019;34(9):2015-22. DOI: 10.2337/dc11-0606
Del Prato S, Nauck M, Durán-Garcia S, Maffei L, Rohwedder
K, Theuerkauf A, et al. Long-term glycaemic response and
tolerability of dapagliflozin versus a sulphonylurea as addon therapy to metformin in patients with type 2 diabetes: 4-
year data. Diabetes, obesity & metabolism. 2015;176:581-
DOI: 10.1111/dom.12459
Sezai A, Tanaka A, Imai T, Kida K, Sekino H, Murohara T,
Sata M, Suzuki N, Node K; CANDLE Trial Investigators.
Comparing the Effects of Canagliflozin vs. Glimepiride by
Body Mass Index in Patients with Type 2 Diabetes and Chronic
Heart Failure: A Subanalysis of the CANDLE Trial. Biomedicines. 2022 Jul 9;10(7):1656. doi: 10.3390/ biomedi cines100
PMID: 35884961
Ridderstråle M, Andersen KR, Zeller C, Kim G, Woerle HJ,
Broedl UC. Comparison of empagliflozin and glimepiride as
add-on to metformin in patients with type 2 diabetes: a 104-
week randomised, active-controlled, double-blind, phase 3
trial. The lancet Diabetes & endocrinology. 2018;2(9):691-
doi.org/10.1111/dom.13457
Riddle MC. A Verdict for Glimepiride: Effective and Not
Guilty of Cardiovascular Harm. Diabetes Care. 2019;42(12):
-3.
Trerattanavong K, Tadi P. Glimepiride. StatPearls. Treasure
Island (FL): StatPearls Publishing Copyright © 2020, StatPearls
Publishing LLC.; 2020.
Melillo G. FDA approves dapagliflozin to treat heart failure,
breaking new ground in SGLT2 competition. American Journal
of Managed Care. 2020;1.
Raj GM, Wyawahare M. Dapagliflozin for heart failure: is
it a class effect?. Future cardiology. 2021 ;17(2):355-61. DOI:
2217/fca-2020-0087
Shao S-C, Chang K-C, Hung M-J, Yang N-I, Chan Y-Y, Chen
H-Y, et al. Comparative risk evaluation for cardiovascular
events associated with dapagliflozin vs. empagliflozin in realworld type 2 diabetes patients: a multi-institutional cohort
study. Cardiovascular Diabetology. 2019;18(1):120. doi.org/
1186/s12933-019-0919-9
Mosleh H, Alenezi M. Prevalence and factors of anxiety and
depression in chronic kidney disease patients undergoing
hemodialysis: A cross-sectional single-center study in Saudi
Arabia. Cureus. 2020;12(1). DOI: 10.7759/cureus.6668
Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA,
List JF. Dapagliflozin add-on to metformin in type 2 diabetes
inadequately controlled with metformin: a randomized, doubleblind, placebo-controlled 102-week trial. BMC medicine.
;11:43. doi: 10.1186/1741-7015-11-43
Rosenstock J, Perl S, Johnsson E, García-Sánchez R, Jacob
S. Triple therapy with low-dose dapagliflozin plus saxagliptin
versus dual therapy with each monocomponent, all added to
metformin, in uncontrolled type 2 diabetes. Diabetes Obes
Metab. 2019 Sep;21;9;2152-2162. doi: 10.1111/dom.13795.
Sjöström CD, Johansson P, Ptaszynska A, List J, Johnsson E.
Dapagliflozin lowers blood pressure in hypertensive and nonhypertensive patients with type 2 diabetes. Diabetes & vascular
disease research. 2015;12(5):352-8. DOI: 10.1177/ 147916411
Yamout H, Perkovic V, Davies M, Woo V, de Zeeuw D, Mayer
C, et al. Efficacy and safety of canagliflozin in patients with
type 2 diabetes and stage 3 nephropathy. American journal
of nephrology. 2014;40(1):64-74. DOI: 10.1159/000364909
Scholtes RA, Muskiet MH, van Baar MJ, Hesp AC, Greasley
PJ, Karlsson C, et al. Natriuretic effect of two weeks of
dapagliflozin treatment in patients with type 2 diabetes and
preserved kidney function during standardized sodium intake:
results of the DAPASALT trial. Diabetes Care. 2021
;44(2):440-7. doi: 10.2337/dc20-2604
Sjöström CD, Hashemi M, Sugg J, Ptaszynska A, Johnsson
E. Dapagliflozin-induced weight loss affects 24-week glycated
haemoglobin and blood pressure levels. Diabetes, obesity &
metabolism. 2015;17(8):809-12. DOI: 10.1177/ 1479164115
Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel
A. Blood Pressure Lowering in Type 2 Diabetes: A Systematic
Review and Meta-analysis. JAMA. 2015;313;6;603–615.
doi:10.1001/jama.2014.18574
Vilsbøll T, Ekholm E, Johnsson E, et al. Efficacy and safety
of dapagliflozin plus saxagliptin versus insulin glargine over
weeks as add-on to metformin with or without sulphonylurea
in patients with type 2 diabetes: A randomized, parallel-design,
open-label, Phase 3 trial. Diabetes Obes Metab. 2020; 22:
–968. https://doi.org/10.1111/dom.13981
Mathieu C, Ranetti AE, Li D, Ekholm E, Cook W, Hirshberg
B, et al. Randomized, Double-Blind, Phase 3 Trial of Triple
Therapy With Dapagliflozin Add-on to Saxagliptin Plus
Metformin in Type 2 Diabetes. Diabetes Care. 2015;38(11)
:2009-17. DOI: 10.2337/dc15-0779
Fadini GP, Bonora BM, Mayur S, Rigato M, Avogaro A.
Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose cotransporter-2 inhibitors. 2018;20(3):740-4. DOI: 10.1111/dom.
Gopal CDSM, Rathi S, Tyagi S. Clinical profile of hypoglycemia in emergency department of tertiary care hospital: A
single center study. International Journal of Advanced Research
in Medicine 2021; 3(1): 340-343.DOI: 10.22271/27069567.
v3.i1f.162
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Muhammad Kamran Yousuf, Khalid Mustafa Memon, Muhammad Sajid Abbas Jaffri, Mehr Fatima, Mamoora Arslaan, Shizma Junejo
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0 
